Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in Preoperative GBM and CNS Metastases
NCT02605746Phase 1Completed
- Sponsor
- St. Joseph's Hospital and Medical Center
- Start
- Feb 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceritinib in glioblastoma (GBM) and brain metastases (3 arms), sponsored by St. Joseph's Hospital and Medical Center. Primary endpoints: Plasma Concentration, Cerebrospinal Fluid Concentration and 1 more. Started Feb 2016; status: completed.
02
Drugs
ceritinib
03
Conditions
glioblastoma (GBM)brain metastases
Beyond the preview
Go deeper on NCT02605746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605746.